Promedior Announces Initiation Of Phase 2a Of Anti-Fibrotic Therapeutic, PRM-151, In The Prevention Of Post-Surgical Scarring In Glaucoma Patients
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced that it has initiated a Phase 2a clinical study of PRM-151 to evaluate the efficacy, safety, and tolerability of PRM-151 in preventing post-surgical scarring in glaucoma patients following glaucoma filtration surgery. There currently are no approved drugs for preventing post-surgical scarring in glaucoma, and there are no approved anti-fibrotic drug therapies in the U.S. or Europe for any fibrotic disease... (Source: Health News from Medical News Today)
KLF6 Gene and Early Melanoma Development in a Collagen I-Rich Extracellular Environment
Signaling from the collagen I-rich extracellular matrix could be involved in the tumor suppressive activity of KLF6 protein. Journal of the National Cancer Institute (Source: Medscape Today Headlines)
